argenx SE reported strong second quarter 2026 financial results, with product net sales reaching $1.5 billion, a 60% increase year-over-year. The company achieved an operating profit of $494 million for the quarter, compared to $201 million in the prior-year period. Net profit for the three months ended June 30, 2026, was $472 million, resulting in a basic profit per share of $7.58. Growth was driven by the expanded VYVGART label in the U.S. to include all gMG serotypes. Total cash, cash equivalents, and current financial assets stood at $5.2 billion as of June 30, 2026. The company is an immunology innovation company developing antibody-based medicines for autoimmune diseases.
